Epidemiologic and Microbiologic Characteristics of Occult Bacteremia Among Febrile Children in Southern Israel, Before and After Initiation of the Routine Antipneumococcal Immunization (2005–2012)  by Ribitzky-Eisner, Haya et al.
Pediatrics and Neonatology (2016) 57, 378e384Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /www.pediatr -neonatol .comORIGINAL ARTICLEEpidemiologic and Microbiologic
Characteristics of Occult Bacteremia Among
Febrile Children in Southern Israel, Before
and After Initiation of the Routine
Antipneumococcal Immunization
(2005e2012)
Haya Ribitzky-Eisner a, Yitamar Minuhin a, David Greenberg b,
Ninel Greenberg c, Gabriel Chodick d, Mihai Craiu c,
Eugene Leibovitz a,b,*a Pediatric Emergency Medicine Department, Soroka University Medical Center, Faculty of Health
Sciences, Ben-Gurion University, Beer-Sheva, Israel
b Pediatric Infectious Disease Unit 2, Soroka University Medical Center, Faculty of Health Sciences,
Ben-Gurion University, Beer-Sheva, Israel
c Pediatric Emergency Medicine Department, Alfred Rusescu Children’s Hospital, Carol Davila Medical
School, Bucharest, Romania
d Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, IsraelReceived Aug 10, 2015; received in revised form Oct 2, 2015; accepted Oct 16, 2015
Available online 8 December 2015Key Words
children;
Kingella kingae;
occult bacteremia;
serotypes;
Streptococcus
pneumoniae;
vaccine* Corresponding author. Pediatric Em
Israel.
E-mail address: eugenel@bgu.ac.il
http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2015, Taiwan P
NC-ND license (http://creativecommoBackground: Little is known about the incidence and dynamics of occult bacteremia (OB)
among infants/young children following the introduction of pneumococcal conjugate vaccines
(PCVs) into the national immunization program in Israel in 2009e2010. The aim of this study
was to characterize the epidemiologic and microbiologic picture of OB among febrile in-
fants/children aged 3e36 months in southern Israel, before and after PCVs introduction.
Methods: Retrospective study enrolling all infants/young children attending the emergency
room of a tertiary medical center in southern Israel with fever without source, discharged,
and reported with a positive blood culture.
Results: Of 453 true bacteremias, 89 (19.6%) were defined as OB. OB rate was 0.22%; a signif-
icant decrease was recorded in OB rates, with the highest rate during 2005 (0.34%) and theergency Medicine Department, Soroka University Medical Center, P.O. Box 151, Beer-Sheva 84101,
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Epidemiologic and Microbiologic Characteristics 379lowest during 2011 (0.15%). OB cases decreased in post-PCV (2010e2012) versus prevaccination
period (2005e2009) from 66/22,256 cases (0.3%) to 23/13,213 cases (0.17%; p Z 0.03). Most
frequent single OB pathogens were Streptococcus pneumoniae, Streptococcus viridans spp.,
and Kingella kingae (39.3%, 10.1%, and 9.0%, respectively); Enterobacteriaceae spp. were iso-
lated in 10 cases (11.2%). No changes were recorded in S. pneumoniae-OB cases; K. kingae-OB
decreased significantly (pZ 0.047). None of the S. pneumoniae serotypes isolated during 2011
e2012 belonged to 13-valent PCV (PCV13). An increase in non PCV13 serotypes was recorded
during 2011e2012 (3/3, 100% vs. 7/32, 21.9%, p Z 0.01).
Conclusion: OB rates decreased significantly following the introduction of PCVs. S. pneumo-
niae was the most frequent isolated pathogen in OB, but in lower percentages compared with
the medical literature. No PCV13 serotypes were detected as a cause of OB during 2011e2012.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
The definition of fever without source and occult bacter-
emia (OB) in the daily pediatric practice may differ be-
tween various studies and various periods of time, leading
to considerable variability in the findings and definitions
required at physical examinations and in the calculation of
its various incidence rates.1e4 Nevertheless, the incidence
of OB was relatively constant (2e10%) until the middle of
1980, with a significant decrease following the introduction
in the routine practice of vaccination against Haemophilus
influenzae type b.5e8 The introduction of the pneumo-
coccal conjugate vaccines (PCVs) was accompanied by an
additional quick and significant decrease in OB cases to
rates under 1%.9e21 Today, the pathogens expected to be
responsible for OB in the era of PCVs are Neisseria menin-
gitidis, Escherichia coli, Staphylococcus aureus, group A
Streptococcus and Salmonella spp., and also nonvaccine
serotypes of Streptococcus pneumoniae.11 The imple-
mentation of the routine vaccination policy with PCV7 in
the United States led to a decrease of 84% and 67% in the
incidence of the bacteremia caused by S. pneumoniae and
bacteremia in general, respectively.11
In Israel, PCV7 was introduced in routine use in July 2009
and changed to PCV13 in November 2010. No information is
available today either at the national level or in southern
Israel regarding the expected changes in the incidence of
OB in infants and children aged 3e36 months vaccinated
with PCVs, and also on the distribution of pathogens and
the therapeutic approach in patients diagnosed with this
syndrome.
The main objective of this study was to describe and
characterize the epidemiologic, microbiologic, and thera-
peutic features of OB among febrile children aged
3e36 months treated at the pediatric emergency room
(PER) in southern Israel, before and after the introduction
of routine PCV vaccination.2. Methods
This was a retrospective study describing the 8 year period
2005e2012. The Soroka University Medical Center is the
only general hospital in southern Israel and providesprimary and tertiary health services to the entire popula-
tion of southern Israel. It served a population of > 800,000
inhabitants in 2012; of these, > 250,000 were children
< 18 years of age. The PER of the hospital accepts around
36,000 visits/y.
In southern Israel, two pediatric populations live side by
side: Jewish children, largely urban with a lifestyle com-
parable to Western populations, and Bedouin children,
formerly composed of desert nomads, and now in transition
to a Western lifestyle. Hospitalization rates due to respi-
ratory and gastrointestinal infections in general, and inva-
sive pneumococcal diseases (IPDs) particularly, are more
prevalent among Bedouin children.14,22e24
Today, all infants in Israel are immunized initially with
three doses of H. influenzae type b vaccine (at the age of
2 months, 4 months, and 6 months) and two doses of the
Prevenar vaccine (Prevenar13 since November 15, 2010, at
the age of 2 months and 4 months), followed by a booster
with both vaccines at the age of 1 year.
The study population included all infants/young children
aged 3e36 months diagnosed in the PER with fever without
source, discharged from the PER, and with a positive blood
culture (with a true pathogen) reported following the visit.
2.1. Data sources
All of the information was retrieved from medical charts
and computerized laboratory data of the study patients. We
analyzed the medical records of all patients with a
discharge diagnosis of: (1) fever without source; (2) sus-
pected OB; and (3) fever only. Patients with immunodefi-
ciencies, malignancies, and the presence of long-term
vascular catheters were excluded. Approval to perform this
study was obtained from the IRB of the Soroka University
Medical Center.
The treatment protocol in children with suspected OB in
the PER required performing blood cultures in every patient
aged 3e36 months with a temperature > 38C. The decision
to treat with antibiotic drugs belonged to the treating
physician, and was based on presence/absence of a pe-
ripheral white blood cell count > 15,000 cells/mm3. In
general, even when leukocytosis > 15,000 cells/mm3 was
present, there was still a recommendation of refraining
from antibiotic treatment if the patient’s family was
Figure 1 Occult bacteremia rates during the study period.
OB Z occult bacteremia.
Table 1 Occult bacteremia: pathogen distribution (in
decreasing frequency).
N %
Streptococcus pneumoniae 35 39.3
Streptococcus viridans 9 10.1
Kingella kingae 8 9.0
Salmonella* 6 6.7
Nonfermentative Gram negative bacilli 5 5.6
Acinetobacter lwoffi 4 4.5
Staphylococcus aureus 4 4.5
Neisseria (Neisseria meningitidis - 2) 3 3.4
Brucella 2 2.3
Escherichia coli* 2 2.3
Enterococcus 2 2.3
Pseudomonas stutzeri 2 2.3
Enterobacter cloacae* 1 1.1
Gram positive cocci 1 1.1
Haemophilus influenzae type b 1 1.1
Klebsiella pneumoniae* 1 1.1
Pantoea agglomerans 1 1.1
Pasteurella multocida 1 1.1
Streptococcus pyogenes 1 1.1
Total 89 100.0
* Enterobacteriaceae spp. Z 10 (11.2%).
380 H. Ribitzky-Eisner et alconsidered compliant and reliable, and an appropriate
follow-up could be assured. When antibiotic treatment was
prescribed, the protocol recommended oral amoxicillin
(80 mg/kg/d in 2 daily doses) or intramuscular/intravenous
ceftriaxone (50 mg/kg once daily), until the results of blood
cultures become available.
2.2. Study conduct
The patients were identified based on the diagnosis at
discharge from the PER together with positive microbiology
diagnoses provided by the microbiology laboratories of the
hospital. We documented patients’ age, sex, ethnicity,
background diseases, clinical presentation, the complete
blood count, microbiological agents responsible for OB and
their susceptibility to antibiotics, and antibiotic treatment
at discharge.
2.3. Microbiology
S. pneumoniae isolates were considered susceptible to
penicillin if the minimal inhibitory concentration (MIC)
values were  0.06 mg/mL, intermediate if penicillin MIC
values were between 0.125 mg/mL and 1.0 mg/mL, and
resistant if MIC values were  2.0 mg/mL. Ceftriaxone in-
termediate resistance was defined by MIC values between
0.5 mg/mL and 1.0 mg/mL, and high resistance by MIC
values > 2.0 mg/mL.
2.4. Statistical analysis
Data were computerized and analyzed with the SPSS
version 19.0 (SPSS Inc., Chicago, IL, USA). Analysis of vari-
ance and the t test were used to compare continuous var-
iables. The Chi-square test and Chi-square test for trend
were used for univariate analysis of contingency tables and
trends over time in OB rates. A p value < 0.05 was
considered statistically significant.
3. Results
Overall, 100,022 children aged 3e36 months visited the PER
during the study period. Of them, 39,822 had a tempera-
ture > 38C. Positive blood cultures were reported in 989
(2.5%) patients; 453 cultures (45.8%) were diagnosed as true
positive, while 536 (54.2%) cultures were considered
contaminated. OB was diagnosed in 89/453 (19.6%) pa-
tients. No cases of recurrent OB were reported. There were
50.6% Bedouin children and 49.4% Jewish children; 55/89
(61.8%) were males. A total of 40/89 patients (44.9%), 33/
89 patients (37.1%), and 16/89 patients (18%) belonged to
the age groups of 3e11 months, 12e23 months, and
24e36 months, respectively.
During the period, the overall rate of OB among febrile
children aged 3e36 months was 0.22% (89/39,822). OB rates
ranged between 0.34% in 2005 and 0.1% in 2011 (Figure 1),
with a significant (pZ 0.02) decrease in linear trend. When
comparing between the pre (2005e2009) and post
(2010e2012) PCV immunization initiation periods, a signif-
icant decrease was recorded in OB rates from 66/22,256(0.3%) to 23/13,213 (0.17%) infants/young children aged
3e36 months (p Z 0.03).
Seventy-three (82%) of the OB patients were previously
healthy. The remaining 16 suffered from various medical
diseases/conditions, and of these, neurological, respira-
tory, and hematological ones (4 diagnosed in each group)
were the most frequently encountered.
The four most frequent single pathogens were S. pneu-
moniae, Streptococcus viridans spp, Kingella kingae, and
Salmonella spp.: 39.3%, 10.1%, 9.0%, and 6.7%, respectively
(Table 1). Enterobacteriaceae spp. as a group was isolated
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children (2 N. meningitidis).
No differences were recorded in the ethnical distribu-
tion (Bedouin children vs. Jewish children) of S. pneumo-
niae (p Z 0.87) and of K. kingae (p Z 0.16). No significant
differences were found between Jewish patients and
Bedouin patients in the distribution of any of the OB
pathogens (p Z 0.41).
No decrease was recorded in the number of the OB cases
caused by S. pneumoniae during the study years (pZ 0.17,
Chi-square for linear trends in proportions). The number of
OB cases caused by K. kingae decreased significantly
(p Z 0.047). The number of cases of OB caused by S. vir-
idans did not decrease during the study years (p Z 0.29).
Leukocytosis > 15,000 cells/mL was recorded in 42.5%
cases, with no difference between Jewish patients and
Bedouin patients.
Of the 35 S. pneumoniae recorded during the study
period, 25 were isolated during 2005e2009 and 10 during
2010e2012 (Table 2). No significant differences were
recorded between the number of OB cases caused by S.
pneumoniae in the period of time following the introduc-
tion of PCV7 (10/23, 43.5%, during 2010e2012) compared
with the prevaccination period (25/66, 37.9%, during
2005e2009; p Z 0.23). This lack of significant difference
was maintained also when the year 2009 (the year whereTable 2 Streptococcus pneumoniae serotype distribution
during the study years e comparison between 2005e2009
and 2010e2012 (in decreasing frequency).
Serotype 2005e2009 2010e2012 Total cases
19A 5 3 8
1 2 1 3
6B 2 1 3
9V 3 0 3
12F 1 1 2
14 2 0 2
19F 2 0 2
23F 2 0 2
3 0 1 1
6A 1 0 1
6C 0 1 1
10A 1 0 1
15B/C 0 1 1
18A 1 0 1
24F 1 0 1
28A 1 0 1
35B 0 1 1
46 1 0 1
Total PCV7* 4 8 12 (34.3)
Additional 6 seroytpes 8 5 13 (37.1)
Total PCV13y 12 13 25 (71.4)
Non PCV13 serotypes 3 7 10 (28.6)
Total 25 10 35 (100.0)
Data are presented as n or n (%).
PCV Z pneumococcal conjugate vaccine.
* Prevenar7 (July 2009) Z 4, 6B, 9V, 14, 18C, 19F, 23F.
y Prevenar13 (November 2010)Z 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14,
18C, 19A, 19F, 23F.PCV7 was introduced, but only in July 2009) was deleted
from calculations (10/23, 43.5%, during 2010e2012 vs. 19/
55, 34.5%, during 2005e2008; p Z 0.29). The most
frequently isolated serotypes (in descending order) during
the whole study period were 19A, 1, 6B, and 9V (8 isolates,
3 isolates, 3 isolates, and 3 isolates, respectively). The
PCV13 serotypes represented 71.4% of all serotypes. No
differences were recorded in S. pneumoniae serotypes
distribution between Jewish children and Bedouin children.
Only one of 10 of the serotypes isolated during 2010e2012
belonged to PCV7 (serotype 6B, 10%, compared with 11/25,
44%, during 2005e2009, p Z 0.11). Serotype 19A was iso-
lated only during 2005e2010 (the pre PCV13 period) and
there were no cases of OB caused by this serotype following
the introduction of PCV13 (2011e2012). None of the S.
pneumoniae serotypes isolated during 2011e2012 belonged
to PCV13. Non PCV13 serotypes 6C, 10A, 12F, 18A, 24F, 28A,
and 46 (1 each) were isolated during 2005e2009, and se-
rotypes 12F, 15B/C, and 35B (1 each) were isolated during
2010e2012. A significant (p Z 0.01) increase was recorded
during 2011e2012 in the percentages of non PCV13 sero-
types compared with the period 2005e2010 (3/3, 100% vs.
7/32, 21.9%).
Overall, 25/35 (74%) and 34/35 (97.1%) of the S. pneu-
moniae isolates were sensitive to penicillin and ceftriax-
one, respectively. Intermediate susceptibility to penicillin
was recorded for 17.1% isolates; only one isolate (2.9%) was
intermediately resistant to ceftriaxone. Four (11.4%) of the
S. pneumoniae isolates were highly resistant to penicillin
(serotypes 14, 19A, 19F, and 23F).
Forty-seven (52.8%) patients did not receive any antibi-
otic treatment at discharge from the PER. Of the 42 pa-
tients treated with antibiotics, oral amoxicillin and
intramuscular/intravenous ceftriaxone (66.7% and 19% of
the treated children, respectively) were the most
commonly used antibiotics. Only one of eight patients with
K. kingae OB was treated with antibiotics.
During the prevaccination period (2005e2009), 33/66
(50%) of OB patients were treated with antibiotics,
compared with nine of 23 (39%) in the postvaccination
period (2010e2012; p Z 0.37). Amoxicillin was prescribed
in the prevaccination period in 22/33 cases (66.7%)
compared with seven of nine cases (77.8%) in the post-
vaccination period (pZ 0.7). Ceftriaxone was prescribed in
seven of 33 cases (21.2%) in the prevaccination period,
compared with one of nine cases (11.1%) in the post-
vaccination period (p Z 0.66).4. Discussion
The introduction of routine use of the PCVs was accompa-
nied by an additional quick and significant decrease in OB
cases to rates < 1%.10,12e17 This decrease accompanied a
significant decrease in the reports of IPDs in various medical
centers in the United States and Western Europe. In Long
Island, NY, USA, among 329 children aged 2e36 months with
fever > 39C who had blood cultures drawn during
2001e2003, the OB rate was 0.91% (3 S. pneumoniae
cases).12 Herz et al11 examined the prevaccination period
(1998e2000) versus the postvaccination period
(2000e2003) in Northern California, USA and found that
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84% decrease in S. pneumoniae bacteremia and to a 67%
decrease in the overall bacteremia rates. During 2003, E.
coli represented one-third, nonvaccine S. pneumoniae se-
rotypes represented one-third, and S. aureus, Salmonella
spp, N. meningitidis, and Streptococcus pyogenes repre-
sented one-third of the pathogens isolated in blood cul-
tures.10 In addition, the study revealed that leukocytosis
> 15,000 WBC/mm3 became a poor predictive factor for
bacteremia in immunized febrile children.10 In San Diego,
CA, USA the rates of the positive cultures for S. pneumoniae
decreased to zero in PCV7 immunized children compared
with 2.4% in nonimmunized children.13 During 2004e2007,
the S. pneumoniae OB rates in a cohort of 8408 children
aged 3e36 months in Phoenix, AZ, USA reached 0.17%.14 In
NC, Waddle et al reported a decrease of 94.6% in the pos-
itive blood culture rates obtained in 275 children immu-
nized with PCV7, together with a 100% decrease in the rates
of blood cultures positive for S. pneumoniae.15 In Spain,
pneumococcal OB rates reached 0.58% among infants and
children aged 3e36 months with fever without source
during 2006e2009, with no evidence of compensatory in-
crease in the rates of OB caused by non PCV7 serotypes.16 In
Italy, the OB rates in 399 enrolled children during
2006e2009 (post vaccination with PCV7) were 0.34% in the
age group 3e36 months and 2% in young infants aged
1e3 months. S. pneumoniae was not isolated in any of the
blood cultures drawn during the study period.17
We describe in the present study the epidemiologic and
microbiologic picture of OB among children aged
3e36 months with fever > 38C in southern Israel before
(2005e2009) and after (2009e2012) the introduction in
routine use of PCVs. We discussed in detail the two periods
of time which characterized the postvaccination era, when
during the first period the immunization was completed
with PCV7, and during the second period (starting from
November 15, 2010 to December 31, 2012) PCV7 was
replaced by PCV13. We showed in our study that: (1) OB
rates were low (0.22%) and decreased significantly
following the introduction of PCVs; (2) S. pneumoniae was
the main pathogen isolated in OB, but in lower (39.3%)
percentages compared with the medical literature, while
Enterobacteriaceae spp, S. viridans, and K. kingae repre-
sented the most frequently isolated pathogens following S.
pneumoniae; (3) there was no decrease in the number of S.
pneumoniae OB cases, but K. kingae OB cases decreased
significantly during the study period; (4) no differences
were recorded in S. pneumoniae OB cases between the
prevaccination to the post-PCVs period; (5) a significant
increase in the number of non PCV13 serotypes was recor-
ded during 2011e2012 compared with 2005e2010; and (6)
none of the S. pneumoniae serotypes isolated during
2011e2012 belonged to PCV13.
Ben-Shimol et al14 reported on IPD epidemiology in
children < 5 years during the 18 months after the initiation
of the national Israeli immunization program with PCV7.
The authors found that in 2009 and 2010, PCV7 serotypes-
IPD incidences were 15.9/100,000 and 5.4/100,000,
respectively (43% decrease and 81% decrease, respectively)
compared to 2003e2007 (mean incidence 27.8). The
respective overall IPD incidence decreases were 23% and
42%. The overall incidence of serotypes not included inPCV13 did not vary significantly during the study period.20
Recently, Ben-Shimol et al25 reported on the sequential
introduction of PCV7/PCV13 on IPD in children < 5 years
and demonstrated an impressive decrease (95%) in the rates
of disease caused by PCV7þ6A in the PCV13 period. The
rates of IPD caused by the additional PCV13 serotypes (1, 3,
5, 7F, and 19A) increased initially by 47%, but subsequently
decreased by 79% (overall 70% reduction during
2004e2013). The authors also reported a two-fold increase
in the incidence of IPD caused by non PCV13 serotypes. In
Texas, Kaplan et al26 showed that following the introduc-
tion of PCV13 in 2010, IPD rates in children decreased by
42% in general and by 53% in children < 24 months of age.
During the same time period, the representation of PCV13
serotypes decreased by 57% together with a relatively mild
increase in non PCV13 serotypes.
Enterobacteriaceae spp. represented the most frequent
OB pathogen following S. pneumoniae (11.2%), when Sal-
monella spp. (6 patients) and E. coli (2 patients) repre-
sented the most frequent isolates in this group. In a
previous study in southern Israel on community-acquired
bacteremia in children during 1992e2001, Gur et al27 re-
ported similar findings, with Enterobacteriaceae spp. iso-
lated as the most common Gram-negative pathogen (36% of
all Gram-negative organisms). Similar to our study, Salmo-
nella spp. and E. coli were the most common representa-
tives of this group.
Streptococcus viridans spp. was the third most common
etiologic agent of OB in our study. This pathogen is
considered part of the normal oropharynx flora and also of
the genital and gastrointestinal systems, is considered the
most frequent etiologic agent of subacute
endocarditis,28e30 and is increasingly identified as a true
pathogen in cancer patients with fever and neutropenia.31
The contribution of this pathogen in diseases diagnosed in
immunocompetent patients was described in patients with
genital and urinary tract infections. The group of Strepto-
coccus milleri (including Streptococcus anginosus, Strep-
tococcus constelatus, and Streptococcus intermedius) was
described in diseases related to pus production and abscess
formation.29,32e34 In a study on the pathogenic role and the
clinical presentations of S. milleri infections, bacteremia
caused by this pathogen was described in 11.4% of the cases
where this pathogen was recovered.35 In our study, the
diagnosis of S. viridans spp. infections as true ones was
made after thorough investigation of the clinical picture
and disease course, together with consideration of the
relevant laboratory examination, and therefore we
consider that the possibility that these isolations repre-
sented contaminated blood cultures is remote.
The high rate of recovery of K. kingae is surprising and
was not described in previous studies. By contrast, this
pathogen is isolated with increasing frequency in osteo-
articular infections, bacteremia, and endocarditis in chil-
dren.36 In Bedouin children, > 95% of the K. kingae
infections are diagnosed at the age of 6e48 months.37,38 As
a result of considerable improvement in isolation and mo-
lecular diagnostic techniques, K. kingae is considered today
an important pediatric pathogen and is responsible for the
majority of the osteoarticular infections in children aged
< 36 months.39 The clinical picture of K. kingae infectious is
not fulminant and the clinical findings are not specific and
Epidemiologic and Microbiologic Characteristics 383are associated, in general, with normal values of inflam-
mation markers.36e39 This pathogen is sensitive to beta-
lactam antibiotics and the infections caused by this path-
ogen improve under antibiotic therapy only, with the
exception of endocarditis cases, where surgical interven-
tion may be needed.40 In our study we found eight cases of
OB caused by K. kingae (9% of all OB cases), and all were
characterized by a mild clinical picture, as typically ex-
pected in OB cases.
This study has some limitations, the main one deriving
from the retrospective method of data collection which, in
a natural way, may have influenced some of the details on
the patients and the disease analyzed. Another limitation
derives from the short period of time (2010e2012) available
for the examination of the changes in OB rates following
the introduction of PCVs.
In summary, OB rates were low during the study period
and decreased significantly during the years following the
introduction of PCVs. We demonstrated a complete disap-
pearance of the vaccine serotypes included in PCV13 during
the past 2 years of the study, together with a significant
increase in the representation of nonvaccine serotypes. S.
pneumoniae continued to be the main pathogen causing OB
in infants and young children aged 3e36 months.
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